KC02
目录号 : GC13023
Structural analog and inactive form of KC01
Cas No.:1646795-60-9
Sample solution is provided at 25 µL, 10mM.
KC02 is a structural analog of KC01 and inactive form of KC01.
The synthesis of KC02 consistently yielded a 4:1 mixture of Z/E isomers, which proved difficult to chromatographically separate. By competitive gel-based ABPP assys, KC02 inhibited ABHD16A (human and mouse) with IC50 value of >10μM, while KC01 is in range of nM. By PS substrate assays, KC02 inhibited human ABHD16A with IC50 value of > 10μM, while KC01 is in range of nM.
Most of these enzymes were also inhibited by the control probe KC02, with the exception of two partial off-targets, ABHD3 and ABHD13. KC02 also inhibited ABHD11 (94%) and LYPLA1 (63%) but did not substantially inhibit ABHD16A (<30%). In situ treatment with KC01 (1μM, 4 h) but not KC02 (1μM, 4 h) blocked the PS lipase activity of membrane fractions from COLO205, K562 and MCF7 cell lines. KC01 and KC02 constitute a suitable pair of active and inactive (control) probes to investigate the function of ABHD16A in cellular systems. Treatment with KC01 but not KC02 (1μM, 4 h) substantially lowered secreted lyso-PSs of the ABHD12-null LCL. All LCLs also showed decreased cellular lyso-PSs following treatment with KC01 but not KC02. KC01 but not KC02 elevated PS lipase activity and reduced in lyso-PS lipase activity in LPS-stimulated macrophages. The LPS-induced increases in lyso-PS and cytokine secretion were both blocked by pretreatment of Abhd12−/− macrophages with KC01 (1μM, 4 h) but not KC02 (1μM, 4 h).
In COLO205 cells, 1μM KC01 but not KC02 showed substantial reductions in the levels of all detected cellular lyso-PSs compared to DMSO-treated control cells. The levels of secreted lyso-PSs (18:1 and 18:0) were also decreased in COLO205 cells treated with KC01 compared to those in KC02- or DMSO-treated cells (4-h treatments of cells in serum-free medium), whereas levels of other secreted lipids (lyso-PCs, lyso-PEs and MAGs) were unchanged across these treatment groups.
KC01, but not KC02, inhibited the PS lipase activity of brain membrane lysates from 2-month-old Abhd12+/+ and Abhd12−/− mice.
Reference:
1.Kamat SS, Camara K2, Parsons WH et al. Immunomodulatory lysophosphatidylserines are regulated by ABHD16A and ABHD12 interplay. Nat Chem Biol. 2015 Feb;11(2):164-71.
Cas No. | 1646795-60-9 | SDF | |
化学名 | 6-(2-oxo-4-tridecyloxetan-3-yl)hexanamide | ||
Canonical SMILES | CCCCCCCCCCCCCC1OC(C1CCCCCC(N)=O)=O | ||
分子式 | C22H41NO3 | 分子量 | 367.57 |
溶解度 | DMF: 5 mg/ml,DMSO: 5 mg/ml,Ethanol: 16 mg/ml,Ethanol:PBS(pH 7.2) (1:5): 0.5 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.7206 mL | 13.6029 mL | 27.2057 mL |
5 mM | 0.5441 mL | 2.7206 mL | 5.4411 mL |
10 mM | 0.2721 mL | 1.3603 mL | 2.7206 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet